23 results about "Infectious peritonitis" patented technology

The invention relates to the technical field of mRNA vaccines, and discloses a feline infectious peritonitis mRNA vaccine as well as a preparation method and application thereof. The feline infectious peritonitis mRNA vaccine comprises mRNA molecules; the mRNA molecule comprises an FIBV-S protein coding sequence as shown in SEQ ID NO: 6. According to the invention, the mRNA sequence for coding the natural FIBV-S protein is modified, so that the FIBV-S protein obtained by translation can be stably maintained at the prefusion conformation and has higher immunogenicity, thereby endowing the mRNA vaccine with a better immune effect and being beneficial to the prevention of feline infectious peritonitis.

The invention belongs to the technical field of biological medicine, and particularly relates to a nanometer antibody aiming at feline infectious peritonitis virus and application of the nanometer antibody. According to the invention, specific nano antibodies 2S-29 and 2S-39 of two novel FIPV S proteins are obtained by screening through a phage display technology, and a double-antibody sandwich ELISA method for detecting FIPV S antigens is provided. The two antibodies have excellent specificity and affinity to the feline infectious peritonitis virus FIPV S protein. A double-antibody sandwich ELISA method established based on the nano antibody has good specificity, repeatability and sensitivity, the lowest detection limit reaches 4 ng / mL, the FIPV S antigen can be rapidly and accurately detected, and a reliable means is provided for early diagnosis of feline infectious peritonitis.

The invention discloses a cat infectious peritonitis virus isolate and application thereof. The cat infectious peritonitis virus is separated from the peritoneal fluid of a 6-month-old female gradient silver cat, the preservation number of the cat infectious peritonitis virus is CGMCC (China General Microbiological Culture Collection Center) No.46420, and the name of the cat infectious peritonitis virus is SHAANXI-FIBV-II-2024. An animal model is successfully established by using the strain.

This invention provides a saRNA vaccine for the prevention of feline infectious peritonitis (FIP). The saRNA vaccine is a composition comprising saRNA A and saRNA B. The assembly elements of the saRNA include: a 5′ UTR, replicases nsp1-nsp4, a subgenomic promoter, a Kozak sequence, nucleic acid sequence A or nucleic acid sequence B, a 3′ UTR, and a polyadenylated tail (polyA). The saRNA vaccine provided by this invention is effective for the immunization prophylaxis of FIP types I and II. Furthermore, based on the development of this vaccine, by replacing the coding sequences of different antigens, it can be extended to the development of vaccines for other coronaviruses or other veterinary pathogens, demonstrating significant technological transfer value and industrialization prospects.

The invention discloses application of ailanone in preparation of a medicine for treating feline infectious peritonitis, and belongs to the field of biological medicine. The change of the expression quantity of the feline infectious peritonitis virus N protein is detected through indirect immunofluorescence and western blot, and the change of the quantity titer of the feline infectious peritonitis virus is detected through TCID50. Results show that ailanone has an obvious effect of resisting the feline infectious peritonitis virus, the inhibitory effect on the feline infectious peritonitis virus is enhanced along with increase of the drug concentration, and the half effective concentration is 0.09 mu M. Meanwhile, drug inhibition tests show that ailanone has no inhibition effect on feline calicivirus. The invention provides a novel therapeutic drug and strategy for treating feline infectious peritonitis.

This invention provides a broad-spectrum mRNA vaccine for the prevention of feline infectious peritonitis (FIP) and its preparation method. The vaccine comprises mRNA molecule 1 and mRNA molecule 2. mRNA molecule 1 contains an LS-FIPV-I MEV-N-M antigen protein coding sequence composed of a self-assembled LS nanoparticle fusion sequence based on a tandem neutralizing epitope of the FIPV type I S protein and a T-cell epitope, as well as antigen-coding sequences of the N and M proteins. mRNA molecule 2 contains an antigen protein coding sequence of an LS nanoparticle structure self-assembled from the FIPV type II S protein receptor domain RBD. This invention, through the combination of two mRNA molecules, can achieve broad-spectrum protection against both FIPV types I and II while mitigating the risk of adverse drug reaction (ADE).

The invention relates to the technical field of veterinary drugs, and particularly provides a polynucleotide molecule composition for preventing cat infectious peritonitis, a chimeric polynucleotide molecule and an mRNA vaccine. In order to overcome the ADE effect caused by S protein full-length antigen in the prior art, FIPV N protein without ADE risk is adopted and is combined with screened S protein specific T cell and B cell epitopes. Core schemes include two classes: one is a separate polynucleotide composition comprising epitope peptides encoding N and S proteins; and 2, a single chimeric polynucleotide encoding N protein and S protein epitope peptides. The polynucleotides are optimized by codons and encapsulated in lipid nanoparticles (LNP) to prepare vaccines. Experiments prove that the vaccine can synergistically stimulate powerful immune response, the survival rate of immune cats is remarkably increased to 80%-100% from standard 40% on the premise that ADE is not caused, and FIP is effectively prevented.

The invention discloses a recombinant FCoV (Fine Coronaviral Virus) as well as a construction method and application of the recombinant FCoV. The recombinant feline coronavirus is obtained by the following steps: transforming a yeast competent cell by using a yeast plasmid containing a 1ab fragment of an I-type feline infectious peritonitis virus HLJ / HRB / 2016 / 10 virus strain and a recMG893511-SDF-2 virus skeleton protein fragment expression cassette to obtain an infectious clone plasmid, then transfecting a cat kidney cell by using the infectious clone plasmid, and carrying out virus rescue. Furthermore, the invention also discloses a construction method of the recombinant feline coronavirus and application of the recombinant feline coronavirus in establishing a feline coronavirus challenge model, evaluating the effect of an anti-FCoV drug for treating feline infectious peritonitis and the immune effect of an FCoV vaccine. The invention is of great significance to further analysis of the virulence research of the feline coronavirus.

The invention discloses a recombinant feline infectious peritonitis double-layer vesicle tracer virus as well as a construction method and application thereof, and belongs to the technical field of bioengineering. A CRISPR / Cas9 mediated homologous recombination technology is used, on the basis of a reverse genetic manipulation platform, an Nsp3 region of plasmid pBAC-FIBV-791146 is replaced with a reporter gene sequence, then the feline infectious peritonitis virus is rescued, and the recombinant feline infectious peritonitis bilayer vesicle tracer virus is formed. The biological characteristics of the strain and the tracing effect of the double-membrane vesicles are measured, it is proved that insertion of the ZsGreen gene does not affect virus proliferation, but the recombinant virus has the characteristic of tracing the double-membrane vesicles, and the recombinant virus can serve as a research tool for monitoring the forming mechanism of the double-membrane vesicles and a drug screening tool for resisting the feline infectious peritonitis virus.

The invention relates to a kit for feline infectious peritonitis virus and application of the kit, and relates to the field of detection of feline infectious peritonitis virus. The kit comprises an amplification system, a detection system and a detection card, the amplification system is used for amplifying a target sequence, the target sequence is selected from SEQ ID NO.1, the amplification system comprises a primer group, the primer group comprises an upstream primer and a downstream primer, the upstream primer is as shown in SEQ ID NO.2, and the downstream primer is as shown in SEQ ID NO.8. The amplification system of the kit can specifically amplify the target sequence of the feline infectious peritonitis virus, can distinguish the feline infectious peritonitis virus from other viruses, and does not have cross reaction with other viruses.

The application relates to a cat infectious peritonitis virus S protein receptor binding region monoclonal antibody and application thereof, relates to the technical field of biology, and aims to provide a cat infectious peritonitis virus S protein receptor binding region monoclonal antibody and application thereof.The amino acid sequence of a heavy chain variable region of the monoclonal antibody is shown in a sequence table SEQ ID NO.1, and the amino acid sequence of a light chain variable region is shown in a sequence table SEQ ID NO.2.The application adopts Western blot and IFA methods to identify the reactivity of MAb, and identifies an antigen epitope recognized by MAb.The antigen epitope is conservative in type I cat coronavirus, which indicates that the monoclonal antibody can recognize various type I FCoV strains, has broad spectrum, and is not accidentally directed to a single strain.The antigen epitope has no cross reaction with type II, which indicates that the specificity is high, can be used for distinguishing type I and type II infections, and has diagnostic application value.

The present application belongs to the technical field of animal medicine, and particularly relates to an immune response modulator based on a chlorine dioxide chelate as well as a preparation method and application thereof. The present application proposes an innovative immune response modulator for effectively treating feline infectious peritonitis. The immune response modulator is prepared by mixing chlorine dioxide with a chelating agent to react and prepare a chlorine dioxide chelate, and then combining the chelate with an immune boosting component and a stabilizer to obtain the immune response modulator with significant curative effect. Through the chelation technology, the toxicity of chlorine dioxide is effectively reduced, thereby reducing the potential harm to the cat body. Meanwhile, the combination of the chlorine dioxide chelate and the immune boosting component can synergistically improve the cellular immunity and humoral immunity response of the cat and enhance the defense capability of the immune system against viruses, thereby effectively improving the treatment effect of feline infectious peritonitis.

The invention discloses a nucleoside prodrug and application thereof in treating feline infectious peritonitis, and belongs to the field of medicinal chemistry. The invention provides a compound as shown in the specification or pharmaceutically acceptable salt thereof, the compound provided by the invention can effectively inhibit feline infectious peritonitis virus (FIPV), the antiviral activity of the compound obviously exceeds that of GS-441524, and meanwhile, the compound has good pharmacokinetic properties, high bioavailability and good solubility, and can be applied to preparation of drugs for treating feline infectious peritonitis virus (FIPV) or other drugs for treating feline infectious peritonitis virus (FIPV) or other drugs for treating feline infectious peritonitis virus (FIPV). The preparation is simple, the synthesis is easy, and large-scale industrial production can be realized.

The invention provides a broad-spectrum mRNA vaccine for preventing feline infectious peritonitis and a preparation method thereof, the vaccine comprises an mRNA molecule 1 and an mRNA molecule 2, the mRNA molecule 1 comprises a self-assembled LS nanoparticle fusion sequence based on a neutralizing epitope of series FIPV type I S protein and a T cell epitope, and the mRNA molecule 2 comprises a self-assembled LS nanoparticle fusion sequence based on series FIPV type I S protein. The LS-FIBV-I MEV-N-M antigen protein coding sequence is composed of the antigen coding sequences of the N protein and the M protein; the mRNA molecule 2 comprises an antigen protein coding sequence which is fused and self-assembled by an FIPV II type S protein receptor structural domain RBD and has an LS nano-particle structure. According to the invention, through the combination of double mRNA molecules, while the ADE risk is avoided, the broad-spectrum protection of the FIPV type I and the FIPV type II is realized.

This invention belongs to the field of biomedicine, specifically relating to a secretory self-assembling nanoparticle mRNA vaccine for feline infectious peritonitis and its application. First, this invention constructs a Ferritin fusion antigen by fusing the RBD or S1 fragment of the FIPV S protein with ferritin. Second, this invention constructs an mRNA encoding the aforementioned Ferritin fusion antigen. The mRNA is delivered into host cells via lipid nanoparticles (LNPs), where it is translated and expressed in the cytoplasm. The Ferritin fusion antigen then forms a nanoparticle structure within the cell using its natural self-assembly properties, eliminating the need for in vitro assembly steps. Compared to traditional nanoparticle vaccines, this method avoids steps such as in vitro induction expression, purification, and adjuvant addition, simplifying the production process, improving immunogenicity, reducing the risk of adverse drug reactions (ADE), and enhancing safety. Furthermore, it significantly improves humoral and cellular immunity.

The present application relates to the technical field of virus detection, in particular to a primer probe combination for feline infectious peritonitis virus serotyping, application and kit thereof. The primer probe combination comprises FIPV N gene specific primer probe, FIPV I serotype S gene specific primer probe and FIPV II serotype S gene specific primer probe. The three groups of primer probes can be used for serotyping identification of FIPV I serotype strain and FIPV II serotype strain. The primer probe combination can be used for differential diagnosis of different serotypes of FIPV by fluorescence quantitative PCR method, and has the advantages of accurate identification, high sensitivity, simple operation, short time consumption and the like, and can provide effective technical means for rapid diagnosis of feline infectious peritonitis virus in China and prevention of feline infectious peritonitis.

In vitro-transcribed (IVT) RNA molecules and uses thereof as a feline infectious peritonitis(FIP) vaccine are described. An example IVT RNA molecule comprises a polynucleotide encoding a Feline Coronavirus (FCoV) nucleocapsid protein antigen, which is optionally loaded in a Lipid Nanoparticle (LNP) formulation and capable of being expressed in vivo.

The invention relates to the technical field of virus detection, in particular to a primer probe combination for serotyping of feline infectious peritonitis virus as well as application and a kit of the primer probe combination. The primer probe combination comprises an FIPV N gene specific primer probe, an FIPVI serotype S gene specific primer probe and an FIPVII serotype S gene specific primer probe. According to the invention, through the three groups of primer probes, the FIPVI serotype strain and the FIPVII serotype strain can be subjected to serotyping identification; the primer probe combination provided by the invention can be used for identifying and diagnosing different serotypes of FIPVs at one time through a fluorescent quantitative PCR method, and has the advantages of accurate identification, high sensitivity, simplicity in operation, short time consumption and the like; and an effective technical means can be provided for rapid diagnosis of clinical feline infectious peritonitis virus and prevention of feline infectious peritonitis in China.

The invention provides a self-assembled ferritin nanoparticle recombinant protein and application thereof in preparation of cat infectious peritonitis virus vaccines, and belongs to the technical field of nano vaccines. The self-assembly ferritin nanoparticle recombinant protein is formed by self-assembly of ST-N-Fel protein, HCV E2-SC protein and IFN gamma-SC protein. According to the invention, the N protein of FIPV is displayed on the surface of the self-assembled ferritin nanoparticle, an immunopotentiator capable of enhancing cellular immunity and a targeting factor are added to optimize the recombinant protein of the self-assembled ferritin nanoparticle, and IFN gamma-SC and HCV E2-SC can be efficiently coupled with ST-N-Fel through covalent linkage between SpyTag and SpyCatcher. The self-assembled ferritin nanoparticle recombinant protein provided by the invention can be used for preparing an FIPV vaccine, and the vaccine has the capability of reducing ADE risk while inducing protective immune response.